FDA Approves Alectinib to Treat Patients With ALK-Positive N

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

Related Keywords

Sebastian Kaulitzki , Roche Alecensa , Ken Culver , Us Food Drug Administration , Genentech , Patients With , Non Small Cell Lung , Non Small Cell Lung Cancer Clinicaltrials ,